Safety issues and managment of toxicities associated with new treatments for multiple myeloma.

Research paper by Annamaria A Brioli, Lars-Olof LO Mügge, Andreas A Hochhaus, Marie M von Lilienfeld-Toal

Indexed on: 25 Jan '17Published on: 25 Jan '17Published in: Expert review of hematology


Introduction In the last decade, the availability of new drugs for the treatment of Multiple Myeloma (MM) significantly improved patients' outcomes. But also raised attention towards a new spectrum of adverse events. Recently, four novel agents with different mechanisms of action (carfilzomib, elotuzumab, daratumumab and panobinostat) have been approved for the treatment of MM. This review aims at providing physicians with the tools to recognize and handle toxicity issues related with these new treatments. Areas covered This review focuses on the management of drug related adverse events of the latest approved drug combinations. New drug combinations under development and still in the phase of approval will be briefly discussed. PubMed was searched using the terms "toxicity", "carfilzomib", "elotuzumab" "daratumumab" and "panobinostat". Phase II and III clinical trials and previously published analyses on toxicities were reviewed. For new drug combination abstracts presented at the latest ASH, ASCO and EHA meetings as well as clinicaltrial.gov website was searched and reviewed. Expert commentary With the development of newer drugs and the availability of different treatment options for MM patients, an accurate evaluation of treatment side effects, their prompt recognition and management is mandatory for all clinical hematologists.